[HTML][HTML] Long-term treatment with corticosteroids of patients with metastatic breast cancer
HA Van Gilse - Cancer Chemother Rep, 1962 - books.google.com
RESULTS Each subdivided class, as well as the combined group, was analyzed. The
number of patients who improved objectively (obj.+) or did not (obj.-) and/or subjectively …
number of patients who improved objectively (obj.+) or did not (obj.-) and/or subjectively …
[HTML][HTML] Genomic and non-genomic effects of glucocorticoids: implications for breast cancer
IB Mitre-Aguilar, AJ Cabrera-Quintero… - … journal of clinical and …, 2015 - ncbi.nlm.nih.gov
Glucocorticoids (GC) are essential steroid hormones for human life. They regulate a series
of important processes by binding with three glucocorticoid receptors (GR) and activating …
of important processes by binding with three glucocorticoid receptors (GR) and activating …
Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer
JF Stewart, RD Rubens, RJB King, MJ Minton… - European Journal of …, 1982 - Elsevier
Two hundred and four patients with progressive locally advanced or metastatic breast
cancer not controllable by local therapy alone, and who had had no prior systemic therapy …
cancer not controllable by local therapy alone, and who had had no prior systemic therapy …
Corticosteroids in the management of prostate cancer: a critical review
C Ndibe, CG Wang, G Sonpavde - Current treatment options in oncology, 2015 - Springer
Opinion statement Corticosteroids have been used in the management of prostate cancer for
over 30 years. Although daily oral corticosteroids have frequently used in conjunction with …
over 30 years. Although daily oral corticosteroids have frequently used in conjunction with …
[HTML][HTML] Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid …
YS Lu, HC Lien, PY Yeh, KH Yeh, ML Kuo… - World Journal of …, 2005 - ncbi.nlm.nih.gov
AIM: To determine how glucocorticoids (GCs) may affect the growth and chemosensitivity of
common carcinoma cells. METHODS: The effect of dexamethasone (DEX) on growth and …
common carcinoma cells. METHODS: The effect of dexamethasone (DEX) on growth and …
Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas
C Zhang, A Marmé, T Wenger… - International …, 2006 - spandidos-publications.com
The glucocorticoid dexamethasone is frequently used as a co-treatment in cytotoxic cancer
therapy, eg to prevent nausea, to protect normal tissue or for other reasons. While the potent …
therapy, eg to prevent nausea, to protect normal tissue or for other reasons. While the potent …
[HTML][HTML] Glucocorticoid therapy and risk of bladder cancer
K Dietrich, A Schned, J Fortuny, J Heaney… - British journal of …, 2009 - nature.com
Background: Use of immunosuppressive drugs post organ transplantation, and prolonged
use of glucorticoids for other conditions have been associated with subsequent risk of …
use of glucorticoids for other conditions have been associated with subsequent risk of …
Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or …
H Ishiguro, T Kawahara, Y Zheng, E Kashiwagi… - Cancer chemotherapy …, 2014 - Springer
Purpose A synthetic glucocorticoid, dexamethasone, was recently shown to inhibit bladder
cancer cell invasion and metastasis through the glucocorticoid receptor (GR) pathway but …
cancer cell invasion and metastasis through the glucocorticoid receptor (GR) pathway but …
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay
TS Block, TI Murphy, PN Munster… - Cancer management …, 2017 - Taylor & Francis
Background Glucocorticoid receptor (GR) activity plays a role in many aspects of human
physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid …
physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid …
Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized …
G Cocconi, G Bisagni, G Ceci, M Bacchi… - Journal of clinical …, 1992 - ascopubs.org
PURPOSE A randomized study comparing low-dose aminoglutethimide (AG) with and
without hydrocortisone (HC) was performed to investigate whether corticosteroid …
without hydrocortisone (HC) was performed to investigate whether corticosteroid …